Relationships between antithrombin activity,anticoagulant efficacy of heparin therapy and perioperative variables in patients undergoing cardiac surgery requiring cardiopulmonary bypass
Restricted accessResearch articleFirst published online November, 2011
Relationships between antithrombin activity,anticoagulant efficacy of heparin therapy and perioperative variables in patients undergoing cardiac surgery requiring cardiopulmonary bypass
Introduction: A study on 149 cardiopulmonary bypass (CPB) patients was performed to elucidate possible relationships between antithrombin (AT) activity and a subject’s clinical profile or surgery characteristics.
Methods: An initial dose (300 IU/kg) of heparin was administered before CPB. Additional boluses (100 IU/kg) were administered if the activated clotting time (ACT)≤460 s. AT activity and hematological parameters were determined preoperatively, during and after CPB, and at 12, 24, 36, and 48 hours post-intervention.
Results: 29.5% patients required an additional dose of heparin during CPB. Preoperative AT was 96.5 ± 13.9% in all but 4 patients. AT was significantly lower during CPB and upon leaving the operating room (59.7%-80.0%). A small, but significant, inverse correlation was observed between AT at the end of CPB and the patient’s age, as well as between basal preoperative AT and total heparin administered.
Conclusions: Patient’s age could be a moderate indicator of AT activity drop and low preoperative AT activity could be a sign of reduced anticoagulant efficacy of heparin during CPB.
GettinsPG. Serpin structure, mechanism, and function. Chem Rev2002Dec; 102(12): 4751–804.
2.
BjörkIOlsonS. Antithrombin, a bloody important serpin. In: ChurchFCunninghamDGinsburgDHoffmanMStoneSTollefsenD, editors. Chemistry and biology of serpins. New York, NY: Plenum Press; 1997: 17–22.
3.
GrossmannRBabin-EbellJMisophM. Changes in coagulation and fibrinolytic parameters caused by extracorporeal circulation. Heart Vessels1996; 11(6): 310–317.
4.
RanucciMDittaABoncilliA. Determinants of antithrombin consumption in cardiac operations requiring cardiopulmonary bypass. Perfusion2004Jan; 19(1): 47–52.
5.
RanucciMFrigiolaAMenicantiLDittaABoncilliABrozziS. Postoperative antithrombin levels and outcome in cardiac operations. Crit Care Med2005Feb; 33(2): 355–360.
6.
LevyJHSniecinskiRM. Activated clotting times, heparin responses, and antithrombin: have we been wrong all these years?Anesth Analg2010Oct; 111(4): 833–835.
7.
StaplesMHDuntonRFKarlsonKJLeonardiHKBergerRL. Heparin resistance after preoperative heparin therapy or intraaortic balloon pumping. Ann Thorac Surg1994May; 57(5): 1211–1216.
8.
AvidanMSLevyJHvan AkenH. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg2005Jul; 130(1): 107–113.
9.
LemmerJHDespotisGJ. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg2002Feb; 123(2): 213–217.
10.
KanbakM. The treatment of heparin resistance with antithrombin III in cardiac surgery. Can J Anaesth1999Jun; 46(6): 581–585.
RanucciMIsgroGCazzanigaASoroGMenicantiLFrigiolaA. Predictors for heparin resistance in patients undergoing coronary artery bypass grafting. Perfusion1999Nov; 14(6): 437–442.
13.
PaparellaDCappabiancaGScrasciaG. Antithrombin after cardiac surgery: implications on short and mid-term outcome. J Thromb Thrombolysis2009Jan; 27(1): 105–114.
14.
SpiessBD. The relationship between coagulation, inflammation and endothelium - a pyramid towards outcomes. Lippincott Williams & Wilkins, Baltimore: 2000:190–196.
15.
ChandlerWL. Effects of hemodilution, blood loss, and consumption on hemostatic factor levels during cardiopulmonary bypass. J Cardiothorac Vasc Anesth2005Aug; 19(4): 459–467.
16.
RanucciMContiDCastelvecchioS. Hematocrit on cardiopulmonary bypass and outcome after coronary surgery in nontransfused patients. Ann Thorac Surg2010Jan; 89(1): 11–17.
17.
EngstromKGAppelbladMBrorssonB. Mechanisms behind operating room blood transfusions in coronary artery bypass graft surgery patients with insignificant bleeding. J Cardiothorac Vasc Anesth2002Oct; 16(5): 539–544.
18.
TanejaRFernandesPMarwahaGChengDBainbridgeD. Perioperative coagulation management and blood conservation in cardiac surgery: a Canadian survey. J Cardiothorac Vasc Anesth2008Oct; 22(5): 662–669.
19.
BasoraMFitaGPaniguaPLitvanHFloAReverterJC. Survey of perioperative hemostasis and transfusion management in cardiac surgery: how do anesthesiologists practice? (in Spanish). Rev Esp Anestesiol Reanim2010Jan; 57(1): 3–10.
20.
ConlanMGFolsomARFinchA. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost1993Sep1; 70(3): 380–385.
21.
WendelHPEcksteinFSFinkE. Increased coagulation and bradykinin release in shed pleural blood during cardiac surgery. Immunopharmacology1999Oct15; 44(1–2): 119–122.
22.
SalisSMazzantiVVMerliG. Cardiopulmonary bypass duration is an independent predictor of morbidity and mortality after cardiac surgery. J Cardiothorac Vasc Anesth2008Dec; 22(6): 814–822.
23.
AvidanMSLevyJHScholzJ. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiol2005Feb; 102(2): 276–284.
24.
DietrichWSpannaglMSchrammWVogtWBarankayARichterJA. The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass. J Thorac Cardiovasc Surg1991Oct; 102(4): 505–514.
25.
LindenMDSchneiderMBakerSErberWN. Decreased concentration of antithrombin after preoperative therapeutic heparin does not cause heparin resistance during cardiopulmonary bypass. J Cardiothorac Vasc Anesth2004Apr; 18(2): 131–135.
26.
ChanTHwangNCLimCH. A statistical analysis of factors predisposing patients to heparin resistance. Perfusion2006Mar; 21(2): 99–103.
27.
RanucciMIsgroGCazzanigaA. Different patterns of heparin resistance: therapeutic implications. Perfusion2002May; 17(3): 199–204.
28.
SpiessBD. Treating heparin resistance with antithrombin or fresh frozen plasma. Ann Thorac Surg2008Jun; 85(6): 2153–2160.
29.
GarvinSMuehlschlegelJDPerryTE. Postoperative activity, but not preoperative activity, of antithrombin is associated with major adverse cardiac events after coronary artery bypass graft surgery. Anesth Analg2010Oct; 111(4): 862–869.
30.
SlightRDBuellRNzewiOCMcClellandDBMankadPS. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth2008Feb; 22(1): 47–52.
31.
DespotisGJSummerfieldALJoistJH. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg1994Dec; 108(6): 1076–1082.
32.
HardyJFBelisleSRobitailleDPerraultJRoyMGagnonL. Measurement of heparin concentration in whole blood with the Hepcon/HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X. J Thorac Cardiovasc Surg1996Jul; 112(1): 154–161.
33.
GarvinSFitzgeraldDCDespotisGShekarPBodySC. Heparin concentration-based anticoagulation for cardiac surgery fails to reliably predict heparin bolus dose requirements. Anesth Analg2010Oct27; 111(4): 849–855.
34.
BullBSKorpmanRAHuseWMBriggsBD. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg1975May; 69(5): 674–684.
35.
GarvinSFitzgeraldDMuehlschlegelJD. Heparin dose response is independent of perioperative antithrombin activity in patients undergoing coronary artery bypass graft surgery using low heparin concentrations. Anesth Analg2010Feb8; 111(4): 856–861.
36.
RanucciM. Perioperative haemostasis and coagulation management in cardiac surgery: a European survey. Eur J Anaesthesiol2007; 24 (Suppl 40): 1–13.
37.
KosterAChewDKueblerWHabazettlHHetzerRKuppeH. High antithrombin III levels attenuate hemostatic activation and leukocyte activation during cardiopulmonary bypass. J Thorac Cardiovasc Surg2003Sep; 126(3): 906–907.
38.
SzefnerJ. Preventing and managing postoperative bleeding in cardiac surgery by controlling disseminated intravascular coagulation. Eur J Anaesthesiol2007; 24 (suppl 40): 59–66.
